Back to top

Analyst Blog

The share price of Incyte Corporation (INCY - Analyst Report) shot up 33.5% on Aug 21, 2013 to close the trading session at $36.04. The stock was buoyed by the positive top-line results from the company’s phase II RECAP trial (n=136) on Jakafi (ruxolitinib) in combination with Roche’s (RHHBY - Analyst Report) Xeloda (capecitabine). Incyte also reached a 52-week high of $37.46 on Aug 21.

The RECAP study evaluated Jakafi in combination with Xeloda in patients suffering from recurrent or treatment refractory metastatic pancreatic cancer. Results from the study revealed that overall survival in patients under the Jakafi arm was higher than the placebo arm. The company intends to present full results from the study at a future scientific meeting.

The study further revealed that treatment with Jakafi significantly improved body weight relative to placebo. The Jakafi-Xeloda combination was also well tolerated during the study.

Incyte now plans to work with the U.S. Food and Drug Administration (FDA) for a phase III study on Jakafi in pancreatic cancer soon.

We note that Jakafi is the first and only approved treatment for patients suffering from intermediate or high-risk myelofibrosis (MF) in the U.S. Jakafi (ex-U.S. trade name: Jakavi) is marketed by Novartis (NVS - Analyst Report) outside the U.S. The drug is also approved by the European Commission to treat adults suffering from primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF. Incyte is looking to expand the drug’s label in other oncology indications as well.

Incyte recorded net product revenues of approximately $54.1 million from Jakafi sales in the second quarter of 2013, up 82% year over year.

We are encouraged by the positive results from Incyte’s RECAP study. We believe successful development and commercialization of Jakafi in other indications should further boost the drug’s sales potential.

Incyte, a biopharma company, currently carries a Zacks Rank #3 (Hold). Actelion Ltd. (ALIOF) appears to be more attractive in the biopharma space with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GTT COMMUNI… GTT 11.65 +4.11%
ALLERGAN IN… AGN 161.82 +3.99%
CLAYTON WIL… CWEI 117.06 +3.73%
GREENBRIER… GBX 69.63 +2.37%
RF MICRO DE… RFMD 12.02 +2.04%